PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18237796.
- Also identified by DOI 10.1016/j.radonc.2008.01.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The novel agent PRIMA-1(met) can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1(met) as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1(met) may therefore act independently of MTp53 status and WTp53 transactivation.
Medical subject headings
- Aza Compounds
- Bridged Bicyclo Compounds, Heterocyclic
- Prostatic Neoplasms
- Radiation-Sensitizing Agents
- Tumor Suppressor Protein p53